690 related articles for article (PubMed ID: 18177922)
21. Coxibs versus combination NSAID and PPI therapy for chronic pain: an exploration of the risks, benefits, and costs.
Hur C; Chan AT; Tramontano AC; Gazelle GS
Ann Pharmacother; 2006 Jun; 40(6):1052-63. PubMed ID: 16720709
[TBL] [Abstract][Full Text] [Related]
22. Gastrointestinal and cardiovascular risk of non-selective NSAIDs and COX-2 inhibitors in elderly patients with knee osteoarthritis.
Turajane T; Wongbunnak R; Patcharatrakul T; Ratansumawong K; Poigampetch Y; Songpatanasilp T
J Med Assoc Thai; 2009 Dec; 92 Suppl 6():S19-26. PubMed ID: 20128070
[TBL] [Abstract][Full Text] [Related]
23. Clinical use and pharmacological properties of selective COX-2 inhibitors.
Shi S; Klotz U
Eur J Clin Pharmacol; 2008 Mar; 64(3):233-52. PubMed ID: 17999057
[TBL] [Abstract][Full Text] [Related]
24. Acetaminophen for osteoarthritis.
Towheed TE; Judd MJ; Hochberg MC; Wells G
Cochrane Database Syst Rev; 2003; (2):CD004257. PubMed ID: 12804508
[TBL] [Abstract][Full Text] [Related]
25. Valdecoxib: a review.
Chavez ML; DeKorte CJ
Clin Ther; 2003 Mar; 25(3):817-51. PubMed ID: 12852704
[TBL] [Abstract][Full Text] [Related]
26. Gastrointestinal damage by non-steroidal anti-inflammatory drugs: updated clinical considerations.
Pellicano R
Minerva Gastroenterol Dietol; 2014 Dec; 60(4):255-61. PubMed ID: 25384803
[TBL] [Abstract][Full Text] [Related]
27. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
; Bhala N; Emberson J; Merhi A; Abramson S; Arber N; Baron JA; Bombardier C; Cannon C; Farkouh ME; FitzGerald GA; Goss P; Halls H; Hawk E; Hawkey C; Hennekens C; Hochberg M; Holland LE; Kearney PM; Laine L; Lanas A; Lance P; Laupacis A; Oates J; Patrono C; Schnitzer TJ; Solomon S; Tugwell P; Wilson K; Wittes J; Baigent C
Lancet; 2013 Aug; 382(9894):769-79. PubMed ID: 23726390
[TBL] [Abstract][Full Text] [Related]
28. [NSAIDs and COX-2-inhibitors: current status].
Kneitz C; Tony HP; Krüger K
Internist (Berl); 2006 May; 47(5):533-4, 536-8, 540. PubMed ID: 16557412
[TBL] [Abstract][Full Text] [Related]
29. The NSAID dilemma: managing osteoarthritis in high-risk patients.
Roth SH; Anderson S
Phys Sportsmed; 2011 Sep; 39(3):62-74. PubMed ID: 22030942
[TBL] [Abstract][Full Text] [Related]
30. [Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?].
Valat JP; Deray G; Héloire F
Presse Med; 2006 Sep; 35 Suppl 1():25-34. PubMed ID: 17870550
[TBL] [Abstract][Full Text] [Related]
31. An evidence-based approach to prescribing nonsteroidal antiinflammatory drugs. Third Canadian Consensus Conference.
Tannenbaum H; Bombardier C; Davis P; Russell AS;
J Rheumatol; 2006 Jan; 33(1):140-57. PubMed ID: 16331802
[TBL] [Abstract][Full Text] [Related]
32. Risk of myocardial infarction associated with selective COX-2 inhibitors: meta-analysis of randomised controlled trials.
Chen LC; Ashcroft DM
Pharmacoepidemiol Drug Saf; 2007 Jul; 16(7):762-72. PubMed ID: 17457957
[TBL] [Abstract][Full Text] [Related]
33. Nonsteroidal anti-inflammatory drugs (NSAIDs), cyxlooxygenase-2 selective inhibitors (coxibs) and gastrointestinal harm: review of clinical trials and clinical practice.
Moore RA; Derry S; Phillips CJ; McQuay HJ
BMC Musculoskelet Disord; 2006 Oct; 7():79. PubMed ID: 17054784
[TBL] [Abstract][Full Text] [Related]
34. Comparing rates of dyspepsia with Coxibs vs NSAID+PPI: a meta-analysis.
Spiegel BM; Farid M; Dulai GS; Gralnek IM; Kanwal F
Am J Med; 2006 May; 119(5):448.e27-36. PubMed ID: 16651060
[TBL] [Abstract][Full Text] [Related]
35. Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.
Rahme E; Nedjar H
Rheumatology (Oxford); 2007 Mar; 46(3):435-8. PubMed ID: 17255138
[TBL] [Abstract][Full Text] [Related]
36. Do COX-2 inhibitors raise blood pressure more than nonselective NSAIDs and placebo? An updated meta-analysis.
Chan CC; Reid CM; Aw TJ; Liew D; Haas SJ; Krum H
J Hypertens; 2009 Dec; 27(12):2332-41. PubMed ID: 19887957
[TBL] [Abstract][Full Text] [Related]
37. [Is there a future for COX-2 inhibitors?].
Yodfat Y
Harefuah; 2004 Nov; 143(11):820-4, 837. PubMed ID: 15603272
[TBL] [Abstract][Full Text] [Related]
38. Hepatotoxicity induced by coxibs: how concerned should we be?
Bessone F; Hernandez N; Roma MG; Ridruejo E; Mendizabal M; Medina-Cáliz I; Robles-Díaz M; Lucena MI; Andrade RJ
Expert Opin Drug Saf; 2016 Nov; 15(11):1463-1475. PubMed ID: 27537326
[TBL] [Abstract][Full Text] [Related]
39. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events.
Hunt RH; Harper S; Watson DJ; Yu C; Quan H; Lee M; Evans JK; Oxenius B
Am J Gastroenterol; 2003 Aug; 98(8):1725-33. PubMed ID: 12907325
[TBL] [Abstract][Full Text] [Related]
40. Lumiracoxib in the management of osteoarthritis and acute pain.
Bannwarth B; Bérenbaum F
Expert Opin Pharmacother; 2007 Jul; 8(10):1551-64. PubMed ID: 17661736
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
